Human immunodeficiency virus and renal transplantation.
Dinavahi
Rajani V
RV
Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, New York, USA. Rajani.Dinavahi@mssm.edu
Mehrotra
Anita
A
Murphy
Barbara T
BT
Huprikar
Shirish
S
D016263:AIDS-Associated Nephropathy / Q000601:surgery* / Q000821:virology; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000493:pharmacokinetics; D023241:Antiretroviral Therapy, Highly Active; D002784:Cholesterol / Q000097:blood; D004347:Drug Interactions; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D006085:Graft Survival; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics; D016030:Kidney Transplantation / Q000009:adverse effects; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
D019380:Anti-HIV Agents; D000960:Hypolipidemic Agents; D007166:Immunosuppressive Agents; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D014280:Triglycerides; D002784:Cholesterol